Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 19/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 19/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 16/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 1.00 |
| ▸ | PRKAB2 | O43741 | 4/20 | 1.00 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 1.00 |
| ▸ | TFDP2 | Q14188 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376061 | 1.00 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL30788331 | 1.00 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437301 | 0.98 | PRKAG1 (0.96) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481470 | 0.94 | PRKAG1 (0.89) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481025 | 0.94 | PRKAG1 (0.89) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481698 | 0.94 | PRKAG1 (0.89) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481331 | 0.94 | PRKAG1 (0.89) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481329 | 0.94 | PRKAG1 (0.88) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481232 | 0.93 | PRKAG1 (0.87) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL29659650 | 0.93 | PRKAG1 (0.87) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500558-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | Rigel Pharmaceuticals, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | claimed |
| WO-2018035128-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | claimed |
| CN-117243950-A | Application of MK-3903 in preparation of medicines for preventing and/or treating ischemic heart disease | 首都医科大学附属北京朝阳医院 | 2023-12-19 | — | — | CN | disclosed |
| US-20220098175-A1 | DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3924343-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11174246-B2 | Direct AMPK activators | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3500558-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | Rigel Pharmaceuticals, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035128-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | disclosed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010037225-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-08 | — | — | WO | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| WO-2010036613-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036613-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174246-B2 | Direct AMPK activators | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAG1 2/4885PRKAB1 5/4885PRKAA2 12/4885 |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
| US-20220098175-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.